Company: IXHL
Filing Date: 2025-10-27
Form Type: DEF 14A
Source: 0001213900-25-102654
Chunk: 28

Company: Incannex Healthcare Inc.
Filing Date: 2025-10-27
Form: DEF 14A
Chunk 28
---
                                                                               
 included in this table, the weighted-average exercise price of such stock options is $14.42 and the weighted-average term-to-expiration 
 is 1.70 years.                                                                                                                          |

| (3) | Reflects the Plan Amendment (as defined below) approved by our stockholders                                                               
 on May 27, 2025. Pursuant to the Plan Amendment, the 2023 Plan contains an “evergreen provision” which provides that the number           
 of shares authorized for issuance of awards under the 2023 Plan will increase on the first day of each fiscal year of the Company         
 (each, a “Fiscal Year”) beginning with the 2026 Fiscal Year commencing on July 1, 2026 and ending on (and including)                      
 the first day of the 2032 Fiscal Year commencing on July 1, 2032, in an amount equal to 5% of the then-outstanding shares of common stock 
 on such dates (each, an “Evergreen Increase”); provided, however, that our board of directors may act to provide that there               
 will be no Evergreen Increase for a Fiscal Year, or that the Evergreen Increase for such Fiscal Year will be a lesser number of shares    
 of common stock.                                                                                                                          |
| (4) | Reflects the 2023 Plan prior to the adoption of the Plan Amendment.                                                                       |

2023 Equity Incentive Plan On November 20, 2023, our board of directors adopted the 2023 Plan. On April 15, 2025, our board of directors approved an amendment to the 2023 Plan (the “Plan Amendment”) to (i) increase the number of shares authorized for the issuance of awards thereunder by 2,700,000 and (ii) to incorporate an evergreen provision to further increase the number of shares reserved for issuance under the 2023 Plan annually. The Plan Amendment was approved by our stockholders on May 27, 2025. Purpose.The purpose of the 2023 Plan is to provide a means through which we and our affiliates may attract and retain key personnel and to provide a means whereby our and our affiliate’s directors, employees, and consultants (and prospective directors, employees, and consultants) can acquire and maintain an equity interest in the Company, or be paid incentive compensation, which may, but need not, be measured by reference to the value of our shares of common stock, thereby strengthening their commitment to the success of the Company and